Disposition of sulfadimidine and its N4-acetyl and hydroxy metabolites in horse plasma.

The study investigates how sulfadimidine, a type of drug, and its various metabolites behave in horse plasma after being administered intravenously. It found that the concentrations of the metabolites were small and tracked alongside sulfadimidine, and the ratio of the drug attached to proteins in the plasma changed depending on the dosage.

Further Explanation of the Research

• Three horses were administered sulfadimidine (SDM), a type of sulfonamide drug, intravenously. The doses were in two levels – 20 and 200 milligrams per kilogram of body weight – and were administered in cross-over trials. A cross-over trial is a type of experiment where subjects (in this case, horses) are given multiple treatments or interventions in random order, and their effects are measured after each treatment.
• The main objective was to study how SDM and its metabolites behaved in horse plasma. Metabolites are substances formed as the body metabolizes or breaks down drugs. Here, the metabolites they studied were N4-acetylsulfadimidine (N4-SDM), 6-hydroxymethyl-4-methyl-pyrimidine (SCH2OH) and 5-hydroxy-4,6-dimethyl-pyrimidine (SOH).
• Plasma concentrations of SDM and its metabolites N4-SDM, SOH, and SCH2OH ran parallel starting at four hours after drug administration, meaning that the levels rose and fell in unison within the bloodstream. The percentages of these metabolites in plasma were small, with N4-SDM at 0.58-0.90%, SOH at 0.83-6.75% and SCH2OH at 0.38-0.71%.
• At the higher dose of 200 mg/kg, the half-life of the drug in the body was slightly longer (6.0, 10.5, 11.0 hours vs 5.0, 9.5, 9.5 hours for the lower dose). This indicates that the body took slightly longer to break down and eliminate the drug when it was given at a higher dose.
• Focusing on how much of the drug was protein-bound in the plasma, the researchers found that the percentage varied with the dose. Protein-binding refers to the drug’s ability to bind to proteins in the blood, which affects how the drug is distributed throughout the body and how quickly it is cleared. The protein binding for SDM was 61.5-73.3% at the lower dose and 50.5-52.1% at the higher dose. Similar variations were observed for the metabolites SOH and N4-SDM. This means that the protein binding capacity of SDM and its metabolites decreases as the dosage increases.
• The protein binding for SCH2OH, recorded at the higher dosage, ranged between 13.8 to 20.0%, suggesting it has a relatively lower affinity for blood proteins compared to the other substances.

This research offers valuable insights into how the drug sulfadimidine behaves within the body after administration, leading to better understanding of its potential effects and side effects in clinical or veterinary practice.